初乳 Colostrum × 運動恢復
The pooled evidence for bovine colostrum as an exercise-recovery aid is weak and largely negative on the outcomes that matter most to consumers.
The pooled evidence for bovine colostrum as an exercise-recovery aid is weak and largely negative on the outcomes that matter most to consumers. Examine's L1 surfaced an 'Exercise Recovery' B (4 studies / 113 participants, Small Increase) as the primary outcome, but the same Muscle Size & Strength block grades the two most direct recovery readouts — Muscle Soreness (D, 5 studies / 135 participants, No effect) and Muscle Protein Synthesis (D, 1 study / 25 participants, No effect) — as showing no effect. The 'Small Increase' on the composite 'Exercise Recovery' row is therefore not corroborated by the underlying mechanistic or symptomatic endpoints. L2 PubMed is consistent with this read: Davison's 2021 narrative review concludes 'limited evidence for effects on body composition and physical performance'; Glowka's 2020 systematic review and meta-analysis (10 RCTs, 239 athletes) finds 'no or a fairly low impact' on athlete immune markers and was Nutricia-funded; the only direct-recovery RCT showing benefit (Kotzamanidis 2018) was very small (n=18), used a low 3.2 g/day dose, was industry-funded (LR Health & Beauty Systems, paid consultant author), and contributes weak signal. The 2024 meta-analysis showing reduced intestinal permeability is a surrogate mechanism, not a recovery endpoint. Major consumer-facing authorities reinforce a negative consensus: Cleveland Clinic explicitly titles its dedicated article 'Bovine Colostrum: Why You Should Skip This Pricey Supplement' and states 'there isn't a lot of strong evidence to back it up' for exercise performance, strength, and faster recovery (named RD Beth Czerwony, 2024-10-07); Mayo Clinic Press characterises the evidence as 'still in early stages'; Harvard publishes nothing on the topic; and the two most authoritative sports-medicine societies (ACSM, ISSN) have issued no position stand and no recommendation. Regulators converge against marketing claims: EFSA rejected all seven Article 13(1) bovine colostrum health claims in 2011 (IDs 1472-1476, 1889, 1890), and FDA issued multiple warning letters (Sovereign 2019/2020, Proper Nutrition 2021, Gold Crown 2019) against disease-treatment claims. This profile — weakest primary endpoints null, only positive direct-recovery RCT small and industry-funded, leading clinic against, top societies silent, regulators rejecting claims — fits D ('No effect' / consensus against benefit) more accurately than the B that the Examine row alone might suggest.
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.366
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 1 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PTT 健身/FITNESS、Dcard 健身、Mobile01 保健版幾乎無人以「初乳」討論運動恢復；社群恢復話題壓倒性集中在乳清蛋白。初乳相關內容多來自業配部落格與廠商文，非匿名社群實測，缺乏在地真實使用經驗共識。
無共識（社群幾乎無針對初乳用於運動恢復的實測討論，恢復話題以乳清蛋白為主）
- 腸胃不適/脹氣、腹瀉（一般初乳衛教與少數使用者反饋，非運動恢復情境的社群共識）
- 牛奶蛋白過敏者不適用
- 充足睡眠與睡眠延長
- 主動恢復與訓練負荷管理
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-recovery-INT-colostrum-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "初乳能改善運動恢復",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 1,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🔴 D 反證據"
}
}